Objectives: This study evaluated the potential of DNase, alginate lyase (AlgL) and N-acetylcysteine (NAC) in enhancing the in vitro bactericidal activity of conventional (free) and vesicle-entrapped (liposomal) gentamicin, amikacin and tobramycin.
Introduction
In cystic fibrosis (CF), the defect in cyclic adenosine monophosphate-regulated chloride ion channels in the epithelial lining of the respiratory system favours the colonization of Gram-negative bacteria (mainly Pseudomonas aeruginosa) resulting in inflammation, compromised pulmonary function and mortality in CF patients. 1 -4 Upon the entry of P. aeruginosa in CF lungs, penetration of mucus surface and colonization is followed by a genetic transformation of non-mucoid to mucoid (alginate-producing) phenotype. 5, 6 Although non-mucoid bacteria are more virulent, they are also better recognized by the immune response, while the mucoid phenotype increases bacterial adherence and resistance to phagocytosis. 6, 7 As the infections progress, bacteria release virulence factors through quorumsensing (bacterial communication), inducing an inflammatory response. 8 Unlike normal airway secretions, the inflammatory response increases concentrations of neutrophil-derived DNA (0.6 -6.6 mg/mL) and filamentous actin (0.1 -5 mg/mL) in the CF mucus, which interact and bind to glycoproteins [e.g. mucin (8 -47 mg/mL)]. 9 -12 The physical interaction of abnormally high concentrations of such factors results in viscous layers (sputum) that cover the epithelial surface, and allow for bacterial adherence and biofilm production.
Depending on the level of pulmonary infection, different therapies are required. At the time of acute exacerbation of the chronic infection, the lung epithelia are covered with thick layers of sputum containing non-motile mucoid P. aeruginosa in biofilms. Aminoglycosides are the antibiotics of choice against P. aeruginosa, yet are restricted due to the risk of systemic adverse events including ototoxicity and nephrotoxicity. 15, 16 Inhalation of aminoglycosides, mainly nebulized tobramycin for the treatment of CF infections, has proved to increase drug concentration in the lungs, improve forced expiratory volume (FEV) and enhance the reduction of P. aeruginosa in the sputum of patients; however, prolonged use raises concerns with regards to bacterial resistance. 17, 18 Recent publications have focused on the treatment of CF patients with recombinant human DNase (rhDNase), which cleaves DNA and decreases sputum viscosity, improves FEV and reduces the risk of pulmonary exacerbations. 19, 20 A 1 year study showed that once-daily doses of aerosolized rhDNase in CF patients significantly lowered positive cultures and increased FEV, while another study suggested that earlier rhDNase treatments for patients with mild lung function impairments is more efficacious. 19, 21 Recent in vitro studies using combinational treatment with alginate lyase (AlgL) and aminoglycosides against alginate-producing P. aeruginosa biofilms are also promising. 22, 23 AlgL is described to reduce negatively charged alginate levels in biofilm and increase bacterial susceptibility to antibiotics and phagocytosis. 6,22 -26 Lastly, utilizing N-acetylcysteine (NAC) in CF trials has received mixed results and recommendations. 27, 28 NAC, as a mucolytic, is known to reduce disulphide bonds between mucins, which leads to changes in sputum composition and thickness, but no significant improvements have been shown in patient health. 29 Since other studies describe the mucin retardation of antibiotics, in particular liposomal antibiotics, it led us to utilize NAC as a possible enhancer.
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We have focused on micro-carrier technologies involving liposomal drug delivery to circumvent the limitations of aminoglycosides and possibly increase their activity in reducing sputum viscosity and alginate or mucin concentrations. A liposomal delivery system allows site-directed and sustained antibiotic delivery into bacterial cells facilitated through fusion between liposomal and bacterial cell membranes. 33, 34 Liposomes are non-toxic, biodegradable vesicles usually made up of a number of phospholipids measuring nanometres to micrometres in diameter. Upon delivery of liposomal drugs to the CF lungs, liposomes may shield the entrapped aminoglycoside from inactivation by the polyanionic components of the CF sputum. The present work was carried out to examine whether: (i) AlgL further enhances the aminoglycoside activity in killing biofilmforming bacteria; (ii) co-treatment with DNase and/or AlgL increases aminoglycoside bactericidal activity against CF sputum; and (iii) mucin retards aminoglycoside bactericidal activity in the presence of NAC.
Materials and methods

Chemical products
Cholesterol and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) were obtained from Northern Lipids Inc. (Burnaby, BC, Canada). Tobramycin was obtained from Sandoz Laboratories (Boucherville, QC, Canada). Gentamicin, amikacin, DNase from bovine pancreas (400-800 kU/mg), AlgL from Flavobacterium sp. (29 000 U/g), porcine gastric mucin, N-acetylcysteine and all other products were obtained from Sigma-Aldrich (Oakville, ON, Canada).
Bacterial cultures
Two clinical P. aeruginosa strains (PA-489121 and PA-489122) were isolated from the lungs of CF patients at Sudbury Regional Hospital (Sudbury, ON, Canada). The reference strain of P. aeruginosa (ATCC 27853) was purchased from PML Microbiologicals (Mississauga, ON, Canada). All strains were grown for 18 h in cation-adjusted Mueller-Hinton (CAMH) broth prior to the experiments. For all experiments, single colonies were suspended to a final concentration of 1Â10 6 cfu/mL in CAMH broth or PBS (160 mM NaCl, 10 mM KH 2 PO 4 , 1 mM MgCl 2 ; pH 7.4).
Preparation of liposomes and entrapment efficiency
Multilamellar liposomes were prepared from a mixture of DMPC and cholesterol (2:1 molar ratio). The liposomal preparation and the percentage of entrapped antibiotic were measured by a microbiological assay as previously described. 34 
MICs
MICs were measured by the microbroth dilution method according to CLSI (formerly NCCLS) guidelines. Serial 2-fold dilutions of free or liposomal antibiotics in CAMH broth were prepared and aliquots of free or liposomal antibiotics (0.25-1024 mg/L) were mixed with 1Â10 6 cfu/mL bacterial culture (final concentration) and incubated at 378C for 18 h. Broth with and without bacteria served as positive and negative controls, respectively.
Biofilm formation
Mucoid (PA-489121) and non-mucoid (PA-489122 and ATCC 27853) P. aeruginosa were grown on CAMH agar overnight. Single colonies were suspended in CAMH broth, standardized to 1Â10 6 cfu/mL in CAMH broth. According to the manufacturer's instructions, biofilm formation was carried out in Calgary biofilm device (CBD) plates by adding 24 mL of the inoculum to the troughs and placing a peg lid on top. The device was placed in an incubator shaker rotating at 50 rpm at 378C. The rotation ensured broth flowed along the channels of the CBD plates. Every 24 h, the bacterial broth was removed and replaced with fresh broth. After 48 h, biofilms formed in the pegs were washed once in PBS for 30 s and four pegs were removed, placed in PBS, sonicated and serially diluted (10-fold) in PBS for bacterial counts prior to the experiment.
Effect of AlgL on biofilm
Biofilms formed on the pegs, prepared as described above, were then submerged into a standard 96-well plate containing 200 mL serial dilutions (2-fold) of the antibiotic formulations from 0-4096 mg/L in CAMH broth, with or without AlgL at a fixed concentration of 20 U/mL. This concentration was chosen as it was sufficient to reduce biofilm formation. 22 Wells containing no antibiotics and/or biofilm pegs were used as controls. The plate was incubated for 18 h at 378C and the lid was removed, soaked and rinsed twice in plates containing 200 mL of PBS and placed in a 96-well plate containing CAMH broth. The biofilm remaining on each peg was removed from the CBD lid by sonication (Fisher Scientific FS20H) for 1 min. Pegs treated with no antibiotic or only AlgL (20 U/mL) were plated to determine bacterial counts. A new plate cover was added and viability in each well was determined after incubation for 24 h at 378C by a spectrophotometer (625 nm) to measure turbidity.
Effect of DNase and AlgL on CF sputum
The sputum samples containing endogenous P. aeruginosa were collected by spontaneous expectoration from six CF patients following informed consent and a protocol approved by the Research Ethics Committee (Sudbury Regional Hospital, Sudbury, Ontario, Canada). Patients' age, name, treatments and exacerbation records were kept confidential by the hospital. Using a bacterial killing assay to measure the enhancing effects of DNase or AlgL on aminoglycosidic activity, aliquots of sputum samples collected within 24 h were used after acquiring identification of samples containing medium or heavy growth of P. aeruginosa. All experiments involved the original pooled sputum and no replicates or other pooled samples were taken. The terms of the approved protocol did not allow the identification of the P. aeruginosa strains in sputum. Thus, the sputum samples, possibly containing a mixture of susceptible and resistant P. aeruginosa strains, were pooled to allow for a homogenous population of bacteria and were quickly diluted 1:10 (w/v) in PBS of which 50 mL ($7Â10 5 cfu/mL) was first added to each well. Then, 25 mL aliquots of PBS alone (negative control) in addition to DNase (12.5-100 mg/L) or AlgL (2.5-20 U/mL) were added to the wells at the final concentrations. After 15 mins, 25 mL aliquots of either free or liposomal antibiotics ($6 -8 mg/mL final lipid content) diluted in PBS were added in order to achieve fixed final concentrations of 512 mg/L. The incubation mixtures were then incubated for 3 h at 378C and the cfu/mL of live bacteria was determined by serial dilutions and plating on Pseudomonas isolation agar plates with overnight incubation. The incubation time was adequate to allow antibiotic/bacteria interaction and eradication. Percentage survival was calculated relative to antibiotic-treated samples without the addition of DNase or AlgL. Experiments were also performed to evaluate the antimicrobial activity against endogenous P. aeruginosa in the presence and absence of DNase and AlgL. As described above, sputum was incubated with increasing concentrations of antibiotics (64-1024 mg/L) and a fixed concentration of DNase (100 mg/L), AlgL (20 U/mL) or both combined. Percentage survival was calculated as above.
Effect of NAC and mucin on bactericidal activity
The minimum bactericidal concentrations (MBCs) of the formulations were determined for an 18 h period for the P. aeruginosa strains by a standard microbroth dilution assay in CAMH broth in the presence and absence of dissolved mucin and NAC. We used porcine gastric mucin as it is relevant to human mucin. 35 The concentration of mucin was chosen as its activity was strongly inhibited at 15 mg/mL. To perform the assay, 100 mL of the bacterial solution [with or without mucin (15 mg/mL) and NAC (1 mg/mL)] were added to a 96-well plate, along with 100 mL of the free or liposomeentrapped antibiotic (serial 2-fold dilutions). CAMH alone was used as positive (no antibiotic) and negative (no bacteria) controls. After 18 h of incubation, aliquots were aspirated from each well and subcultured on CAMH agar plates overnight. MBC was defined as the lowest concentration of the antibiotic that resulted in ,30 cfu live bacteria/Petri dish. The inhibitory effects of mucin alone, on the bactericidal activity of the formulations, were measured using the same method mentioned above for a 3 h period. This assay was performed to measure the inhibitory effect of increasing mucin concentrations in a short period of time. A mucin stock (60 mg/mL) was dissolved in a bacterial solution and diluted accordingly to 2, 10 and 30 mg/mL mucin. Aliquots of 100 mL of the bacterial solutions (containing mucin) were mixed with 100 mL of bactericidal concentrations of the antibiotics (Table 3 ). The bactericidal concentrations were adequate to eradicate the bacteria within the 3 h incubation period. After incubation, the suspensions were kept cool on ice and bacterial suspensions were diluted 1-10 000-fold in PBS. Wells treated in the absence of mucin were plated without dilutions to display the bactericidal action of the antibiotics. An aliquot of 100 mL of each dilution was plated on CAMH agar and incubated overnight at 378C. The cfu/mL values were then determined for each of the three independent experiments.
Data analysis
Comparisons of groups were made by one-way ANOVA using InStat 3 from GraphPad (GraphPad Software Inc., Version 5.0) followed with Dunnet post t-test. P values were considered significant when *P,0.05 and **P,0.01.
Results
Liposome size and entrapment
The average size of the liposomal formulations ranged from 345.1+42.7 nm to 512.3+88.8 nm ( Table 1 
AlgL treatment of biofilms
After a 48 h incubation period, P. aeruginosa biofilms of ATCC 27853 (6.6+0.4 logs), PA-489121 (6.2+0.5 logs) and PA-489122 (4.7+0.2 logs) were formed per peg. The pegs were transferred to wells containing antibiotic formulations (0 -4096 mg/L) with AlgL. After an 18 h incubation period, positive bacterial counts did not significantly increase (P . 0.05), and treatment of biofilm pegs with AlgL (20 U/mL) did not reduce bacterial counts significantly (P . 0.05, data not 
Sputum treatment with DNase and AlgL
The effects of DNase or AlgL on the bactericidal activities of the different antibiotic formulations on P. aeruginosa in CF sputum were measured (Figure 1 ). When DNase (12.5-100 mg/L) or AlgL (2.5-20 U/mL) was co-incubated with 512 mg/L of each formulation, neither combination completely eradicated growth. Overall, a marked drop in viable bacteria compared with controls (antibiotic alone) was noticed (P,0.05). Liposomal antibiotic formulations did not significantly (P.0.05) fair better than free antibiotics except when gentamicin and AlgL were used in combination. When DNase (100 mg/L) and AlgL (20 U/mL) were kept at optimal concentrations and concentrations of the antibiotics (64-1024 mg/L) were increased, antimicrobial activity gradually reduced cfu counts (Figure 2 ). Although there was not a significant (P. 0.05) difference between free or liposomal antibiotics in their bactericidal activity, the presence of DNase, AlgL or both significantly improved bacterial killing compared with antibiotic alone. When AlgL or DNase/AlgL, but not DNase, was utilized, the activity of tobramycin decreased cfu counts significantly (P,0.05). Neither DNase, AlgL nor DNase/AlgL improved gentamicin activity when compared with gentamicintreated CF sputum. The addition of DNase reduced amikacin activity in free or liposomal form when compared with amikacin treatment alone, while AlgL slightly increased this activity (P.0.05). However, the combination of DNase and AlgL significantly (P,0.05) improved bacterial killing for free amikacin, but not liposomal amikacin.
Bacterial killing in the presence of mucin and NAC
Bactericidal activities of the free and liposomal aminoglycosides against the mentioned strains in the presence of mucin and NAC were measured. When the MBCs of the formulations were determined (Table 3) in the presence of mucin, free aminoglycoside concentration increased 2-to 8-fold while that of liposomal forms increased 8-to 32-fold. The addition of NAC as a mucolytic agent at the concentration chosen failed to improve bactericidal activity as the majority of MBCs were equal to mucin-treated samples. Separately, incubation with increasing mucin concentrations generally inhibited the antibacterial activity of liposomal aminoglycosides more than that of free aminoglycosides, as shown for ATCC 27853 at concentrations of 1 and 15 mg/mL only (Figure 3 ). At 1 mg/mL mucin, free tobramycin was not inhibited, while cfu counts of liposomal tobramycin increased by up to 2 logs in PA-489122 only. At 5 mg/mL mucin, all formulations were generally inhibited up to 4 logs (results not shown). At 15 mg/mL mucin, all liposomal formulations were completely inhibited, but free formulations of the antibiotics were generally not inhibited significantly.
Discussion
Aggressive treatment with antibiotics improves the quality of life in patients infected with P. aeruginosa. Intermittent treatments with aminoglycosides have improved the health status of CF patients. However, abnormal concentrations of polyanionic DNA, actin and, to a lesser extent, mucin and alginate increase viscoelasticity and reduce antibiotic diffusion. 36, 37 The property of liposomes to protect encapsulated agents and their direct administration at localized sites has rendered liposomes as a reservoir from where the entrapped agent can be released for prolonged periods of time at the site of infection at therapeutic concentrations. In our studies, we utilized liposomes composed of a DMPC/cholesterol mixture where the uncharged phosphatidylcholine makes it less likely to interact with cellular surfaces, while the addition of cholesterol further enhances liposomal stability. These findings are consistent with results presented in previous studies examining the entrapment of aminoglycosides in liposomes composed of the neutral 1,2-dipalmitoyl-snglycero-3-phosphocholine (DPPC) and cholesterol. 38 Although the antimicrobial effectiveness of aminoglycosides entrapped in DPPC/cholesterol liposomes was superior to that of the free antibiotics, their delivery in DMPC/cholesterol might prove to be even more efficacious since DMPC's gel-to-fluid phase transition occurs at a lower temperature (248C versus 378C for DPPC), thus allowing a more complete release of its antibiotic content. The chronic infection and resistance of P. aeruginosa in the CF lung appears to arise from the presence of biofilm consisting of alginate-producing mucoid phenotypes. To analyse the antimicrobial activity of aminoglycosides against adhered biofilms, we initially validated their effectiveness against planktonic bacteria ( Table 2 ). The results from the MIC experiments showed that the liposomal antibiotics were not more effective than the free antibiotics against susceptible ATCC 27853 and resistant mucoid PA-489121 (except for liposomal gentamicin), but were more effective against the non-mucoid strain PA-489122 (except for liposomal tobramycin). After 48 h, biofilms were formed and MBECs were measured in the presence of AlgL (Table 2) . Although MBECs were improved with AlgL, there was no significant difference between free and liposomal forms. AlgL did not display an improvement in MBECs for non-mucoid PA489122. Bayer et al. 24, 25 investigated the in vitro and in vivo models of AlgL with antibiotic treatment and reported that the bactericidal effects of amikacin against mucoid strains increased when treated with AlgL compared with non-mucoid strains. The inability of liposomes to further enhance the antimicrobial activity of aminoglycosides in the presence of alginate might be attributed to the interaction of the liposomal lipids with the alginate, thus preventing their interaction with the bacterial membrane. To our knowledge the interaction of alginate and liposomal antibiotics has not been investigated, but previous studies describe an alginate/lipid interaction and alginate insertion within the cationic phospholipids bilayer that increases liposome content release in an unusual 'burst'. 39, 40 It is conceivable that such an interaction might destabilize the liposomal system resulting in the premature release and inactivation of the positively charged antibiotics.
When DNase or AlgL was used against CF sputum co-treated with aminoglycosides, a marked improvement in bactericidal Figure 1 . Co-treatment of DNase and AlgL and aminoglycosides on CF sputum. Pooled sputum was diluted and incubated with free (F) or liposomal (L) tobramycin (TOB), gentamicin (GEN) and amikacin (AMK) (final concentrations of 512 mg/L) in the presence of (a-c) DNase (12.5-100 mg/L) or (d-f ) AlgL (2.5-20 U/mL). Percentage survival was calculated relative to antibiotic-treated samples without the addition of DNase or AlgL. P values were considered significant when compared with the control: *P,0.05; **P,0.01. activity was noticed. However, the liposomal antibacterial activity in the presence of DNase and AlgL was comparable to that seen with the free antibiotics (Figure 1 ). An earlier study by Sanders et al. 41 confirmed that sputum overwhelmingly blocked the transport of nanospheres and the transfer was partially restored with rhDNase. At this time, we cannot delineate why liposomal aminoglycosides were not more effective than free aminoglycosides, as liposomes can deliver a higher dose of antibiotics to the bacteria. One can argue that the stability of the liposomes (over 3 h of incubation) was affected in a way where antibiotic release was hampered, thus preventing bacterial interaction. Results from recent stability studies carried out in our laboratory indicate that the release of tobramycin from liposomes occurs at slower rates in the presence of sputum (70% retention after 3 h of incubation) than in the absence of sputum (M. Alipour, Z. E. Suntres, M. Halwani, A. O. Azghani and A. Omri, unpublished data). The data of this study further indicate that the presence of AlgL is more effective than DNase in increasing bacterial killing by aminoglycosides and the activity of aminoglycosides increased with an increased concentration of either of the enzymes. DNase may be less superior than AlgL as it does not affect bacterial resistance as much as sputum viscosity. In fact, Hunt et al. 32 found that rhDNase decreased tobramycin activity by increasing the concentration of smaller negatively charged DNA strands that bound to tobramycin. The antibacterial activity of aminoglycosides was also improved when DNase and AlgL were combined ( Figure 2 ) compared with when they were used alone. A study by Stern et al. also demonstrated the inhibition of the transfer of a reporter gene in liposomes by CF sputum to several cell-lines and the ability of DNase, more than AlgL, to allow transfection. Mrsny et al. 43, 44 have shown the ability of rhDNase over AlgL to reduce viscosity and their additive response together against CF sputum. The results also point to the fact that, of the three aminoglycosides used, tobramycin was more effective against the sputum. While tobramycin is used as an effective agent against P. aeruginosa, we cannot speculate if the prior treatments of patients had led to increased susceptibility of bacteria to tobramycin or if tobramycin was more effective in general against these clinical strains in sputum.
The ability of liposomes to penetrate the CF sputum dictates their effectiveness against pathogens in the CF lungs. For this, potential inhibition by large glycoproteins (i.e. mucin) against the above-mentioned strains and the reduction of mucin-binding with the addition of NAC were measured. Indeed, studies have shown that mucin has a high affinity towards tobramycin, higher than DNA, and this binding is concentration-dependent. 32, 45 In general, the presence of mucin at 15 mg/mL (Table 3 ) raised the MBCs up to 8-and 32-fold for free and liposomal aminoglycosides, respectively. Co-treatment with NAC at 1 mg/mL did not improve bactericidal activity. In a shorter incubation period of 3 h, with increasing mucin concentrations, liposomal aminoglycosides did not display higher activity than their corresponding free aminoglycosides ( Figure 3) . Inhibition of bacterial killing was noticed at low concentrations of 1 mg/mL and bacterial counts were almost completely restored at concentrations of 15 mg/mL. This decrease Log cfu/mL Figure 3 . Antibiotic activity against P. aeruginosa in the presence of mucin. Free (F) or liposomal (L) tobramycin (TOB), gentamicin (GEN) and amikacin (AMK) at bactericidal concentrations (Table 3) were incubated with or without mucin (1 and 15 mg/mL) for the non-mucoid ATCC 27853. CAMH broth alone was used as a positive control (no antibiotic). P values were considered significant when compared with the control: **P, 0.01. Table 3 . Effect of mucin and NAC on the MBCs for P. aeruginosa
MBC (mg/L)
Conditions F-TOB L-TOB F-GEN L-GEN F-AMK L-AMK in activity could be due to a restriction of penetration of large vesicles amongst mucin/bacteria, while free aminoglycosides, although inhibited, had a higher interaction with bacteria. Our liposomes consisted of uncharged lipids; a recent study by Zaru et al. 31 determined that the charge and composition of liposomes affect their binding to mucin. It has been reported that muco-adhesion, which occurs between oppositely charged molecules, was much higher in uncharged liposomes (46.2%) than negatively charged liposomes (25.1%). The binding of liposomes, and their restriction of movement, may account for liposomal inhibition by mucin. This could also be a possible reason for reduced activity of aminoglycosides by sputum. As DMPC liposomes are neutral, interactions with mucin within the sputum may have reduced bacterial binding and antibacterial bioactivity.
Although liposomal aminoglycosides have been found to be more effective than their free forms against P. aeruginosa under normal in vitro conditions, our experiments do not display an advantage of liposomes in the presence of mucin. Also, in the treatment of biofilms and CF sputum, conventional and liposomal aminoglycosides were strongly inhibited and activity was only restored when DNase and AlgL were introduced. It should also be stressed that the success against sputum was achieved in a tenth of its dilution. In a clinical setting, AlgL that could be prepared as nebulizers co-administered with free or liposomal antibiotics must have a higher concentration than that of 20 U/mL. The concentrations required and implications of AlgL in infection models have yet to be determined by our group. However, as the majority of CF patients produce sputum in their lungs, co-administration of DNase and AlgL with liposomal antibiotics will reduce sputum viscosity and increase antimicrobial activity as shown above, which may be a huge advantage as it could help increase penetration of the sputum barrier.
